The relationship between academia and industry is key to successful translation. University technology-transfer offices can loom large in this relationship. On page 830, Meredith Wadman discusses concerns that some of these offices are more of a hindrance than a help. Closer collaboration, in which industry pays universities to solve problems that it defines, might be one solution (see page 853). More radically, a book reviewed on page 855 argues that the entire drug industry should be restructured, with research and development pried free from marketing.
The concept that translational research is a one-way flow from bench to bedside is seen by many as outdated. Clinical data and human trials can inspire insights that flow from bedside to bench, too, as Heidi Ledford reports on page 843. The observation that some anti-inflammatory drugs may delay the onset of Alzheimer's disease, for example, has led one group to find out how they block formation of dangerous protein products (see pages 861 and 925), which may help to refine the drugs. And pages 863 and 921 detail progress towards a transgenic monkey model for Huntington's disease.
Riches abound. If these discoveries can be carried to the clinic, biomedicine will be all the richer. 
